tbuckley/cabot-search huggingface dataset:
Case 49-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, George L. Nardi, Austin L. Vickery
Journal: New England Journal of Medicine (1980)

Presentation of CaseA 50-year-old woman was admitted to the hospital because of fever and abdominal pain.Diabetes mellitus was found 15 years before admission and was regulated with diet and isophane insulin. Two years before entry a diagnosis of primary hypothyroidism was established, and treatment with levothyroxine was instituted. Thirteen months before admission she entered another hospital because of diarrhea and fever. A stool culture yielded salmonella organisms. Pain developed in the right upper abdominal quadrant, and a cholecystectomy was performed. The gallbladder was hydropic and contained stones 3 to 6 mm in diameter; the cystic duct was small. . . .
MB-105THE EARLY OUTCOMES OF PROTON THERAPY FOR MEDULLOBLASTOMA ON THE PEDIATRIC PROTON CONSORTIUM REGISTRY
Authors: Andrew Chang, Torunn Yock, Atman Pai
Journal: Neuro-Oncology (2016)

MB-105. THE EARLY OUTCOMES OF PROTON THERAPY FOR MEDULLOBLASTOMA ON THE PEDIATRIC PROTON CONSORTIUM REGISTRY Andrew Chang1,3, Torunn Yock2, and Atman Pai3; ProCure Oklahoma City, Oklahoma City, OK, USA; Massachusetts General Hospital, Boston, Massachusetts, USA; Scripps San Diego Proton Therapy Center, San Diego, CA, USA INTRODUCTION: Medulloblastoma is among the most common brain tumors diagnosed in children in the United States. Post-operative cranio-spinal irradiation (CSI) is an important part of treatment regimens for the treatment of medulloblastoma. Proton therapy has demonstrated improved dosimetric advantages in CSI as compared to x-ray based radiotherapy. In the United States, medulloblastoma is one of the most common pediatric malignancies treated in proton therapy centers. The Pediatric Proton Consortium Registry (PPCR) was established as a multi-institutional registry to track and follow outcomes of pediatric patients treated with protontherapy.Weaim to evaluate the early outcomes of patients treated with proton CSI who have been enrolled on the PPCR. METHOD: The PPCR databased was queried for all patients with a diagnosis of medulloblastoma. Of the 146 patients identified, 55 patients had follow-up information at the time of the date of the data entry deadline. The average age at start of CSI for all patients was 8.7 years; 91 patients were male, and 55 female. Intent of treatment was curative for 129 patients, palliative in 2, and unrecorded in the remainder. RESULTS: At a medium follow up of 12.3 months, overall survival was 87.3%. Progression-free survival was 89.7% with local failure occurring in 6.9% and metastatic disease in 10.3%. CONCLUSION: Early outcomes from proton therapy are comparable to historic x-ray therapy outcomes. Longer follow-up is ongoing and will be needed for evaluation of the putative benefit of long-term toxicity reduction. Neuro-Oncology 18:iii97–iii122, 2016. doi:10.1093/neuonc/now076.100 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
&lt;italic&gt;N&lt;/italic&gt;-Nitrosamines in Smoke Condensate From Several Varieties of Tobacco&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Donald E. Johnson, John W. Rhoades
Journal: JNCI Journal of the National Cancer Institute (1972)

N-Nitrosamines in Smoke Condensate From Several Varieties of Tobacco Get access Donald E. Johnson, Donald E. Johnson Department of Chemistry and Chemical Engineering, Southwest Research Institute, San Antonio, Texas 78284 Search for other works by this author on: Oxford Academic PubMed Google Scholar John W. Rhoades John W. Rhoades Department of Chemistry and Chemical Engineering, Southwest Research Institute, San Antonio, Texas 78284 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Pages 1845–1847, https://doi.org/10.1093/jnci/48.6.1845 Published: 01 June 1972
Financing the medical management of mental disorders
Authors: S S Sharfstein, H Goldman
Journal: American Journal of Psychiatry (1989)

In 1987 Medicare benefits for the mentally ill were expanded for the first time in 22 years. A major change was the removal of limits and copayments for the "medical management of psychopharmacologic agents." Payment for medical management recognizes the trend toward the remedicalization of psychiatry; however, medical management can be defined either broadly or narrowly. The authors suggest pricing strategies for both medical management of mental disorders and psychotherapy. Enlightened design of psychiatric benefits will cover all forms of treatment according to appropriate rules. Access to treatment for mental illness is at stake as these rules develop.
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Authors: Nitu Bansal, Monica Bartucci, Shamila Yusuff, Stephani Davis, Kathleen Flaherty, Eric Huselid, Michele Patrizii, Daniel Jones, Liangxian Cao, Nadiya Sydorenko, Young-Choon Moon, Hua Zhong, Daniel Medina, John Kerrigan, Mark N. Stein, Isaac Y. Kim, Thomas W. Davis, Robert S. DiPaola, Joseph Bertino, Hatem E. Sabaawy
Journal: Clinical Cancer Research (2016)

Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1 regulates stem cell self-renewal, impairing BMI-1 function for TIC-tailored therapies appears to be a promising approach.We have previously developed a combined immunophenotypic and time-of-adherence assay to identify CD49bhiCD29hiCD44hi cells as human prostate TICs. We utilized this assay with patient-derived prostate cancer cells and xenograft models to characterize the effects of pharmacologic inhibitors of BMI-1.We demonstrate that in cell lines and patient-derived TICs, BMI-1 expression is upregulated and associated with stem cell-like traits. From a screened library, we identified a number of post-transcriptional small molecules that target BMI-1 in prostate TICs. Pharmacologic inhibition of BMI-1 in patient-derived cells significantly decreased colony formation in vitro and attenuated tumor initiation in vivo, thereby functionally diminishing the frequency of TICs, particularly in cells resistant to proliferation- and androgen receptor-directed therapies, without toxic effects on normal tissues.Our data offer a paradigm for targeting TICs and support the development of BMI-1-targeting therapy for a more effective prostate cancer treatment. Clin Cancer Res; 22(24); 6176-91. ©2016 AACR.
The study of nevi in children: Principles learned and implications for melanoma diagnosis
Authors: Alon Scope, Michael A. Marchetti, Ashfaq A. Marghoob, Stephen W. Dusza, Alan C. Geller, Jaya M. Satagopan, Martin A. Weinstock, Marianne Berwick, Allan C. Halpern
Journal: Journal of the American Academy of Dermatology (2016)
Psychomotor epileptic symptoms in six patients with bipolar mood disorders
Authors: D O Lewis, M Feldman, M Greene, Y Martinez-Mustardo
Journal: American Journal of Psychiatry (1984)

Of 12 consecutive patients with bipolar mood disorders satisfying DSM-III criteria, six were discovered to have five or more psychomotor epileptic symptoms. All of the six had olfactory hallucinations, metamorphopsias, and multiple déjà vu or mystical experiences. Each of them responded to lithium carbonate and had a first-degree relative with a bipolar disorder. The authors suggest that psychomotor symptoms may be more prevalent in bipolar patients than has hitherto been recognized.
Soundings: Fear and clothing
Authors: Trisha Greenhalgh
Journal: BMJ (2001)

Two weeks ago, at a conference in South Africa, Wendy Orr told how, as a young prison doctor in 1983, she had exposed evidence of police torture and abuse of political detainees under the apartheid regime. At the time, Dr Orr was placing her career and perhaps even her life on the line. But she was driven by the belief that her sole duty as a doctor was to serve the sick. Overseeing (and implicitly condoning) a system that directly damaged her patients' health was a compromise she was not prepared to make.

She reminded us that while the moral dilemmas she personally had faced were stark and, she hoped, unique, doctors frequently had to weigh commercial or political expedience against the needs and human rights of their patients.

The first email I opened on my return to the United Kingdom was a request that highlighted the thin end of this ethical wedge. Channel 4 plans to put together a new television series called Model Behaviour about the search for a UK supermodel. Ten girls (sic) aged between 16 and 22 are to be selected from auditions across the UK, placed together in a flat in London, and given modelling assignments. Using a method similar to that used in Big Brother, they will be whittled down (sic) over a couple of months to one winner who will be given a modelling contract.

The programme organisers are said to have recognised that the situation will be “very stressful” and have already enlisted a nutritionist and a psychotherapist to be on hand. They are also looking for a female general practitioner to carry out physical examinations (some of them filmed) on the selected hopefuls, to be “available” if health problems arise during the series, and to be interviewed about what symptoms and signs she might be looking for.

A camera on the dressing room wall of 10 attractive young women who share naive ambition, a high risk of eating disorders, and fierce competition for a glamorous future promises to make compelling TV. Cut-in shots of a nice lady doctor reassuringly taking blood pressures and adjusting the psychological thermostat will surely help to quell the public outcry at the exploitation of vulnerable young women whose understanding of the risks involved must be questionable. Will the profession unite to distance itself from such a charade?
The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways
Authors: Xiang Xiao, Xiaomin Shi, Yihui Fan, Chenglin Wu, Xiaolong Zhang, Laurie Minze, Wentao Liu, Rafik M. Ghobrial, Peixiang Lan, Xian Chang Li
Journal: Immunity (2016)
Bilateral Nephrocalcinosis
Authors: J T Kwan, F P Marsh
Journal: New England Journal of Medicine (1996)

Figure 1. A 39-year-old woman presented with a seven-year history of renal calculi. A plain abdominal film obtained when she was 38 (Panel A) showed enlarged kidneys bilaterally with nephrocalcinosis in a papillary distribution and radiopaque calculi in both ureters (arrows). An intravenous urogram done at the same time (Panel B) showed left-sided hydronephrosis. A collection of stones passed by the patient over a two-month period is shown in Panel C. Analysis of the stones showed that the majority were composed of calcium oxalate, with some composed of magnesium ammonium phosphate. Urine cultures showed intermittent coliform infection, with no evidence . . .
Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study.
Authors: Peter H. O'Donnell, Elizabeth R. Plimack, Joaquim Bellmunt, Raanan Berger, Robert B. Montgomery, Karl Heath, Marisa Dolled-Filhart, Kumudu Pathiraja, Christine K. Gause, Jonathan D. Cheng, Rodolfo F. Perini, Shilpa Gupta
Journal: Journal of Clinical Oncology (2015)

296 Background: Pembro, an anti-PD-1 monoclonal antibody, has shown antitumor activity in several advanced solid tumors. The safety, tolerability, and antitumor activity of pembro in pts with recurrent or metastatic urothelial cancer was assessed in a cohort of KEYNOTE-012 (Clinicaltrials.gov: NCT01848834). Methods: PD-L1 expression was assessed in archival or newly obtained tumor samples from pts with advanced carcinoma of the renal pelvis, ureter, bladder, or urethra using a prototype immunohistochemistry assay. Only pts with PD-L1 expression in stroma or ≥1% of tumor cells were eligible. Pts received pembro 10 mg/kg every 2 wks until complete response, progression, or unacceptable toxicity. Pts deriving benefit could remain on pembro beyond initial progression. Response was assessed every 8 wks per RECIST v1.1 by the investigator and by independent central review (primary efficacy end point). Results: 33 pts enrolled (n=30 with transitional cell histology; median age, 70 y [range 44-85]; ECOG PS 1, 70%; 2 prior therapies for advanced disease, 52%; liver metastases, 21%). 22 pts (67%) received ≥3 pembro doses. Median follow-up duration was 11 mos (range 10-13), and 7 pts (21%) remain on therapy. At least 1 drug-related AE was reported by 61% of pts, most commonly fatigue (n=6), peripheral edema (n=4), and nausea (n=3). Grade 3-4 drug-related AEs were reported for 4 pts (12%), with only rash seen in &gt;1 pt (n=2). 29 pts received ≥1 dose of pembro and had a baseline scan with measurable disease and were evaluable for response. ORR was 24% (95% CI, 10%-44%) by investigator review, with 7 partial responses. ORR by central review was also 24% (95% CI, 10%-44%), with 3 (10%) complete and 4 (14%) partial responses. Response duration is 16-40+ wk (median not reached) by both investigator and central review. ORR in key subgroups, including visceral vs. nodal metastasis, will be presented. In pts evaluable for response, median PFS is 8.8 wks by investigator review and 8.6 wks by central review. In all pts, median OS is 9.3 mos (6-mo OS rate, 58%). Conclusions: Pembro shows acceptable safety and tolerability and provides promising antitumor activity in pts with advanced urothelial cancer. Evaluation of pembro for the treatment of urothelial cancer is ongoing. Clinical trial information: NCT01848834.
Case 30-1972
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Peter C. Block, Robert E. Scully
Journal: New England Journal of Medicine (1972)

Presentation of CaseA 25-year-old man was admitted to the hospital because of abdominal swelling and dyspnea.He had been well until nine months previously, when he began to experience substernal burning that was relieved by the ingestion of food; he lost 7 kg in weight. A physician prescribed an antacid, and his symptoms subsided, with recovery of the lost weight. Six months before admission there was the insidious onset of abdominal swelling and exertional dyspnea. A single episode of dizziness was followed by brief loss of consciousness. Five months before entry he had an illness characterized by malaise and . . .
MB-91OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE
Authors: Ashley Szpurko, Katrina O'Halloran, Jim Potts, Christopher Dunham, Karen Goddard, Jeffrey Davis, Caron Strahlendorf, Shahrad Rod Rassekh, Juliette Hukin
Journal: Neuro-Oncology (2016)
DEATH FROM LOWER NEPHRON NEPHROSIS COMPLICATING ACUTE CATATONIC EXCITEMENT
Authors: ALFRED J. GIANASCOL
Journal: American Journal of Psychiatry (1955)

1. A case of acute catatonic excitement terminated by fatal lower nephron nephrosis is described. 2. The importance of anticipating and precluding such a progression of pathophysiology is emphasized. 3. Available studies on the fluid, metabolic, and electrolyte balance of such hyperactive psychotic patients are minimal and await further elucidation.
Q&amp;A: Crystal Mackall, John Maris on Pediatrics
Authors: Crystal Mackall, John Maris
Journal: Cancer Discovery (2013)

Abstract Crystal Mackall, MD, chief of the Pediatric Oncology Branch of the National Cancer Institute, and John Maris, MD, director of the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia and professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, discuss some challenges in pediatric cancer research.
Thomas Cromwell
Authors: Thomas B. Cole
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibody-Dependent Cellular Cytotoxicity to a Syngeneic Gross Virus-Induced Lymphoma 2
Authors: Manuel Ortiz de Landazuri, Eli Kedar, John L. Fahey
Journal: JNCI Journal of the National Cancer Institute (1974)

Normal W/Fu rat lymphoid cells exerted a specific cytotoxic effect on syngeneic (C58NT)D tumor cells in the presence of sera from W/Fu rats immune to Gross virus-induced lymphoma. The antibody-dependent cellular cytotoxicity (ADCC) reaction did not produce detectable release of nonspecific cytotoxic substances, was not diminished by inhibitors of complement, and was more sensitive in detecting antibodies than a test requiring the external addition of complement. After a single immunization, activity began at day 10 and was maximum about 30–40 days after tumor inoculation. ADCC activity was greatest with peripheral blood Iymphocytes, intermediate with spleen cells, and only slightly positive with lymph node cells. Thymus and bone marrow were always negative. There was no correlation between the capacity to mediate ADCC and the ability to bind to antibody-coated target cell (e.g., form rosettes with antibody-sensitized erythrocytes) in the various normal lymphoid organs.
AT-20INTEGRATED PATHWAY ANALYSIS OF RHABDOID TUMOR SUBTYPES IDENTIFIES KEY SMARCB1-DEPENDENCIES AND THERAPEUTIC OPPORTUNITIES
Authors: Martina A. Finetti, Alicia Del Carpio-Pons, Jocelyn P. Wong, Sarah Batting, James Barker, James Wood, Sirintra Nakjang, Stephen Crosier, Amanda Smith, Matthew P. Selby, Ras A. Ramli, Yura Grabovska, Achim Treumann, Paul H. Huang, Simon Bailey, Steven C. Clifford, Daniel Williamson
Journal: Neuro-Oncology (2016)
&lt;emph type="ital"&gt;Muir Glacier&lt;/emph&gt;
Authors: Janet M. Torpy
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of the Extent of Resection With Survival in Glioblastoma
Authors: Timothy J. Brown, Matthew C. Brennan, Michael Li, Ephraim W. Church, Nicholas J. Brandmeir, Kevin L. Rakszawski, Akshal S. Patel, Elias B. Rizk, Dima Suki, Raymond Sawaya, Michael Glantz
Journal: JAMA Oncology (2016)

<h3>Importance</h3> Glioblastoma multiforme (GBM) remains almost invariably fatal despite optimal surgical and medical therapy. The association between the extent of tumor resection (EOR) and outcome remains undefined, notwithstanding many relevant studies. <h3>Objective</h3> To determine whether greater EOR is associated with improved 1- and 2-year overall survival and 6-month and 1-year progression-free survival in patients with GBM. <h3>Data Sources</h3> Pubmed, CINAHL, and Web of Science (January 1, 1966, to December 1, 2015) were systematically reviewed with librarian guidance. Additional articles were included after consultation with experts and evaluation of bibliographies. Articles were collected from January 15 to December 1, 2015. <h3>Study Selection</h3> Studies of adult patients with newly diagnosed supratentorial GBM comparing various EOR and presenting objective overall or progression-free survival data were included. Pediatric studies were excluded. <h3>Data Extraction and Synthesis</h3> Data were extracted from the text of articles or the Kaplan-Meier curves independently by investigators who were blinded to each other’s results. Data were analyzed to assess mortality after gross total resection (GTR), subtotal resection (STR), and biopsy. The body of evidence was evaluated according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria and PRISMA guidelines. <h3>Main Outcome and Measures</h3> Relative risk (RR) for mortality at 1 and 2 years and progression at 6 months and 1 year. <h3>Results</h3> The search produced 37 studies suitable for inclusion (41 117 unique patients). The meta-analysis revealed decreased mortality for GTR compared with STR at 1 year (RR, 0.62; 95% CI, 0.56-0.69;<i>P</i> &lt; .001; number needed to treat [NNT], 9) and 2 years (RR, 0.84; 95% CI, 0.79-0.89;<i>P</i> &lt; .001; NNT, 17). The 1-year risk for mortality for STR compared with biopsy was reduced significantly (RR, 0.85; 95% CI, 0.80-0.91;<i>P</i> &lt; .001). The risk for mortality was similarly decreased for any resection compared with biopsy at 1 year (RR, 0.77; 95% CI, 0.71-0.84;<i>P</i> &lt; .001; NNT, 21) and 2 years (RR, 0.94; 95% CI, 0.89-1.00;<i>P</i> = .04; NNT, 593). The likelihood of disease progression was decreased with GTR compared with STR at 6 months (RR, 0.72; 95% CI, 0.48-1.09;<i>P</i> = .12; NNT, 14) and 1 year (RR, 0.66; 95% CI, 0.43-0.99;<i>P</i> &lt; .001; NNT, 26). The quality of the body of evidence by the GRADE criteria was moderate to low. <h3>Conclusion and Relevance</h3> This analysis represents the largest systematic review and only quantitative systematic review to date performed on this subject. Compared with STR, GTR substantially improves overall and progression-free survival, but the quality of the supporting evidence is moderate to low.
The Origin of Some Inbred Mice. II. Old Techniques and New&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: L C STRONG
Journal: JNCI Journal of the National Cancer Institute (1955)

The Origin of Some Inbred Mice. II. Old Techniques and New, Get access Leonell C. Strong Leonell C. Strong Roswell Park Memorial Institute, Biological Station, Springville, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1417–1426, https://doi.org/10.1093/jnci/15.Supplement_5.1417 Published: 01 April 1955